Dr. Caulin received his PhD from the Universidad Autonoma of Madrid, studying alterations in epidermal differentiation during skin carcinogenesis. He did a post-doctoral training at The Burnham Institute focused on cellular processes involved in epithelial cell apoptosis. He then moved to Baylor College of Medicine where he became Assistant Professor of Dermatology-Research, specialized in oncogenic activities that promote squamous cell carcinoma progression. In 2010 he moved to MD Anderson Cancer Center to continue his work on head and neck cancer development. In 2018 he joined the Department of Otolaryngology at the University of Arizona as Associate Professor and Director of Translational Head/Neck Cancer Research.
Carlos Caulin, PhD
Associate Professor, Cancer Biology - GIDP
Associate Professor, Otolaryngology
Director, Translational Head/Neck Cancer Research
Member of the Graduate Faculty
Associate Professor, Otolaryngology
Director, Translational Head/Neck Cancer Research
Member of the Graduate Faculty
Research Interests
Our lab investigates biological mechanisms involved in head and neck cancer. We are interested in studying how mutations that accumulate in tumor epithelial cells contribute to cancer development, modulate the immune microenvironment of the tumors, and promote resistance to therapy, including immunotherapies. We generate mouse models tailored to study these processes, and use these mice to conduct relevant preclinical studies and to identify mechanisms of resistance to therapy. We perform cross-species analyses of the tumors generated in these mice and human head and neck cancers to identify new cancer drivers and to refine therapeutic strategies.
Education and Training
Graduate Education:
PhD: Universidad Autonoma de Madrid, Madrid, Spain
Publications
2024
"Dynamics of The Γδtcr Repertoires During The Dedifferentiation Process and Pilot Implications for Immunotherapy of Thyroid Cancer.", Adv Sci (Weinh), pp. e2306364, 2024 Jan 29.
PMID: 38286670(link is external) ,
2023
"Spontaneous Murine Model of Anaplastic Thyroid Cancer.", J Vis Exp, issue 192, 2023 Feb 03.
PMID: 36804915(link is external) ,
"Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.", J Clin Oncol, vol. 41, issue 22, pp. 3851-3862, 2023 Aug 01.
PMID: 36977289(link is external) ,
2022
"Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment.", Nat Commun, vol. 13, issue 1, pp. 6619, 2022 Nov 04.
PMCID: PMC9636408(link is external) PMID: 36333338(link is external) ,
2021
"Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention.", Curr Treat Options Oncol, vol. 22, issue 6, pp. 52, 2021 May 15.
PMCID: PMC8122210(link is external) PMID: 33991232(link is external) ,
"Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models.", Cancers (Basel), vol. 13, issue 6, 2021 Mar 23.
PMCID: PMC8005156(link is external) PMID: 33806894(link is external) ,
"Characterizing dedifferentiation of thyroid cancer by integrated analysis.", Sci Adv, vol. 7, issue 31, 2021 Jul.
PMCID: PMC8318367(link is external) PMID: 34321197(link is external) ,
2020
"Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer.", J Natl Cancer Inst, vol. 112, issue 3, pp. 266-277, 2020 Mar 01.
PMCID: PMC7073912(link is external) PMID: 31124563(link is external) ,
2017
"PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.", Cancer Prev Res (Phila), vol. 10, issue 12, pp. 684-693, 2017 Dec.
PMCID: PMC5716880(link is external) PMID: 29018057(link is external) ,